Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
The Food and Drug Administration (FDA) has approved the Proclaim™ Plus spinal cord stimulation (SCS) system featuring FlexBurst360™ therapy for the treatment of chronic, intractable pain of the trunk and/or limbs.
FlexBurst360 therapy builds upon Abbott’s proprietary BurstDR stimulation technology, providing pain coverage across up to 6 areas of the trunk and/or limbs. Using the Proclaim Plus SCS system, physicians can identify the lowest effective dose of stimulation for each patient and adjust it based on evolving pain needs.
Individuals can access therapy settings using either a mobile device or through a Company-provided mobile device. The system can also be used with Abbott’s NeuroSphere™ Virtual Clinic, allowing individuals to communicate with a clinician via a secure in-app video chat and receive remote programming adjustments.
The Proclaim Plus SCS system is recharge-free with a battery life lasting up to 10 years.
This article originally appeared on MPR
References:
FDA approves Abbott’s new spinal cord stimulation device; provides tailored relief to multiple pain areas and adds more treatment options for evolving pain conditions. News Release. Abbott. Accessed August 23, 2022. https://abbott.mediaroom.com/2022-08-23-FDA-Approves-Abbotts-New-Spinal-Cord-Stimulation-Device-Provides-Tailored-Relief-to-Multiple-Pain-Areas-and-Adds-More-Treatment-Options-for-Evolving-Pain-Conditions#assets_2429_124556-111
